<DOC>
	<DOCNO>NCT00762346</DOCNO>
	<brief_summary>A multicenter prospective study ass efficacy safety ZOMETA® treatment high-level NTX non small cell lung cancer bone metastasis .</brief_summary>
	<brief_title>Efficacy Safety Study ZOMETA® Treatment High-level NTX Non Small Cell Lung Cancer With Bone Metastasis</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<criteria>Age &gt; 18 Histologically confirm nonsmall cell cancer One bone metastasis least confirm image ( X ray , CT others ) NTX &gt; 50nM BCE/mM creatinine Life expectancy &gt; 6 M ECOG &lt; = 2 Signed ICF Women pregnant lactation Patients hyperostosis brain metastasis ( exception without symptom Metastasis Lesions control Previous current treatment bisphosphonates , bone protecting , cytotoxic target therapy Severe comorbidity type may interfere assessment patient study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>non small cell lung cancer</keyword>
	<keyword>NTX</keyword>
	<keyword>zometa</keyword>
</DOC>